LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Pancreatic ductal adenocarcinoma (PDAC) presents a significant challenge due to limited therapeutic options.
• Laminins, particularly LAMC2, are implicated as potential diagnostic and prognostic markers in PDAC.
• Identifying novel molecular targets is crucial for developing effective inhibitory strategies against PDAC.

Purpose of the Study:

• To investigate the cellular, functional, and clinical relevance of LAMC2 in PDAC.
• To elucidate the LAMC2-regulated network and identify potential therapeutic targets.
• To explore dual-drug combinations involving LAMC2 inhibition for PDAC treatment.

Main Methods:

• LAMC2 expression analysis in PDAC tissues, cell lines, and mouse models.
• Genetic perturbation studies in 2D, 3D, and in vivo models.
• RNA-sequencing for LAMC2 network profiling and analysis of public gene expression datasets.
• Investigation of dual inhibition strategies targeting LAMC2-regulated effectors.

Main Results:

• LAMC2 is consistently upregulated in PDAC models and human specimens, correlating with tumor grade and survival.
• LAMC2 inhibition reduces cell proliferation, induces apoptosis, and sensitizes PDAC cells to MEK1/2 inhibitors.
• A LAMC2-regulated network, including the FOSL1-AXL axis, was identified and found to interact with the KRAS signaling pathway.
• Combined genetic LAMC2 or pharmacological AXL inhibition with MEK1/2 inhibitors demonstrated synergistic antiproliferative effects across various PDAC models.

Conclusions:

• LAMC2 serves as a viable molecular target in PDAC.
• The LAMC2-regulated network provides insights into a novel dual-drug combination strategy for cancer treatment.
• Targeting LAMC2 in conjunction with MEK1/2 inhibitors presents a promising therapeutic avenue for PDAC.